SerMa (Seroma of the Mammary Gland)
- PI: Prof. Dr. Nina Ditsch
- Study supported by EUBREAST
- Trial design: Trial design: Prospective, interventional, multicenter non-AMG/MPG study to detect possible markers for prediction and risk assessment of a breast seroma after skin-sparing mastectomy and implant breast reconstruction
- Primary endpoint: Discovery of immune markers for risk assessment of developing a seroma, analysis of the microbiome diversity and differentiation between a specific immune reaction and a general infection in development of a seroma.
https://classic.clinicaltrials.gov/ct2/show/NCT05899387
Study expected to start in Q1 2024